Sarepta Gene Therapy Risks - Search News

Order byBest matchMost fresh

News

Gene Therapy Stays on Market Despite FDA Request

· 2d · on MSN

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its key gene therapy treatment appeared at risk. The Food and Drug Administration will request that the company voluntarily stop all shipments of the treatment, Elevidys, a person familiar with the matter told CNBC.

Continue reading

BioPharma Dive · 2d

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks

· 1d · on MSN

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

Axios on MSN50m

Drugmaker refuses FDA request to pull gene therapy

An unusual public feud between the Food and Drug Administration and a maker of gene therapies for rare diseases could test ...

Fierce Biotech2d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results